Therapeutic gain factors for fractionated radiation treatment of spontaneous murine tumors using fast neutrons, photons plus O2(1) or 3 ATA, or photons plus misonidazole
- PMID: 3205910
Therapeutic gain factors for fractionated radiation treatment of spontaneous murine tumors using fast neutrons, photons plus O2(1) or 3 ATA, or photons plus misonidazole
Abstract
Therapeutic gain factors (TGFs) have been determined for three spontaneous tumors of the C3H mouse treated by photons + normobaric oxygen (O2(1) ATA), photons + hyperbaric oxygen (O2 3 ATA), photons + misonidazole, or fast neutrons. The tumors were early generation isotransplants of spontaneous tumors: MCaIV, a mammary carcinoma; FSaII, a fibrosarcoma; and SCCVII, a squamous cell carcinoma. The tumors, transplanted to the right leg, were 6 mm at start of treatment. Normal tissue responses studied were acute reaction of normal skin (all treatment modalities) and LD50 following irradiation of the upper abdomen (in test of photons + O2 at 1 or 3 ATA). Thus both the tumor and normal tissues would be classified as "acute responding." All subject tissues were at congruent to 34.5-35 degrees C at irradiation. Treatments were based on d(25)Be or p(43)Be fast neutron beams, 60Co and 137Cs photon beams. Treatments were given in 5 or 15 equal doses in 5 days. For photon treatments, TGFs (air/O2 3 ATA) were substantially and significantly larger than 1 for all three tumor systems treated at small or large doses per fraction when related to skin or abdominal tissue responses. The TGFs (air/O2 1 ATA) were greater than 1 at small doses per fraction for MCaIV and FSaII for skin as the normal tissue; the TGFs for all three tumors and at all doses per fraction would be greater than 1 when related to upper abdominal tissues. TGFs (O2 1 ATA/O2 3 ATA) for photon irradiation greater than 1 were found only for SCCVII and that obtained for both large and small doses per fraction. Misonidazole achieved impressive TGFs (air/air + miso or air/O2 1 ATA + miso); the drug was tested only at 10-12 Gy/fraction and relative to skin. RBEs(FN) for the three tumors were lower at 1.5-2 Gy(FN)/fraction than at 5-6 Gy(FN)/fraction, i.e. the opposite to that reported for normal tissue (RBE increases with decreasing dose per fraction). A TGF (relative to skin reaction) greater than 1 for fast neutron therapy was found only for SCCVII when treated at large doses/fraction; this was true for air or O2 1 ATA conditions.
Similar articles
-
Pentobarbital anesthesia and the response of tumor and normal tissue in the C3Hf/sed mouse to radiation.Radiat Res. 1985 Oct;104(1):47-65. Radiat Res. 1985. PMID: 4048394
-
Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole in vivo on FSaII murine fibrosarcomas.J Natl Cancer Inst. 1987 Aug;79(2):377-81. J Natl Cancer Inst. 1987. PMID: 3474467
-
Independent effect of a mixed-beam regimen of fast neutrons and gamma rays on a murine fibrosarcoma.Radiat Res. 1984 Apr;98(1):96-106. Radiat Res. 1984. PMID: 6718698
-
New understanding from Cf brachytherapy trials and considerations for neutron therapy of bulky gyn carcinoma for future.Strahlenther Onkol. 1994 May;170(5):253-63. Strahlenther Onkol. 1994. PMID: 8197547 Review.
-
[Dermatofibrosarcoma protuberans. Results of radiosurgical therapy by photon and electron rays or fast neutrons].Strahlenther Onkol. 1988 Jun;164(6):319-22. Strahlenther Onkol. 1988. PMID: 3133798 Review. German.
Cited by
-
[A linear quadratic analysis of the effect of different fractionation patterns on local tumor control: a study on human squamous-cell carcinomas in nude mice].Strahlenther Onkol. 1998 Oct;174(10):536-8. doi: 10.1007/BF03038988. Strahlenther Onkol. 1998. PMID: 9810323 German. No abstract available.
-
Oxygen distributions partly explain the radiation response of human squamous cell carcinomas.Br J Cancer Suppl. 1996 Jul;27:S185-90. Br J Cancer Suppl. 1996. PMID: 8763877 Free PMC article.
-
Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer.Vaccines (Basel). 2020 Apr 14;8(2):182. doi: 10.3390/vaccines8020182. Vaccines (Basel). 2020. PMID: 32295135 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials
Miscellaneous